Ondansetron, a selective serotonin-type 3 (5-HT 3 ) receptor antagonist, was used to test the hypothesis that duodenal infusion of isosmotic solutions of Polycose or its hydrolytic product glucose, suppressed intake through 5-HT 3 receptors. Polycose suppressed sucrose intake across both concentrations infused (132mM, 7.6 ± 0.6 ml; 263mM, 2.3 ± 0.5 ml), compared to intake under control conditions (12.6 ± 0.3 ml, P <0.001). Pretreatment with 1.0 mg/kg ondansetron attenuated reduction of sucrose intake induced only by the highest concentration of Polycose (4.6 ± 0.8 ml, P=0.004). Dose response testing revealed that suppression of food intake by 263mM
INTRODUCTION
The presence of nutrients in the intestine elicits signals essential to feedback control of ingestion. Considerable advances have been made in understanding the mechanisms by which nutrients in the intestine suppress intake in a number of species (30, 33) , including rats (42, 51, 53) , and humans (74) . For example, it is well documented that intestinal carbohydrates reduce food intake in a dose-responsive manner (53, 76) by pre-absorptive (63, 78) , as well as postabsorptive (71) factors, largely through vagal afferent pathways (78, 79) . However, the complete mechanism(s) by which intestinal oligosaccharides or monosaccharides are perceived to elicit negative feedback control of intake is not known. Administration of the alpha-glucosidase inhibitor, acarbose, attenuates reduction of food intake and c-Fos-immunoreactivity by maltotriose (62, 63) . Moreover, inhibition of sodium-dependent glucose transporter 1 (SGLT 1 ) by intestinal phloridzin infusion, fails to attenuate suppression of food intake and vagal afferent activation by maltotriose or glucose, even though the transport of glucose to the blood is almost entirely blocked (62, 63) . These findings suggest that reduction of food intake by intestinally infused carbohydrates requires hydrolysis to glucose, but that transport of glucose to the blood is not necessary. Since vagal afferent terminals do not penetrate between epithelial cells or protrude into the lumen (3), the receptive mechanism by which intestinal glucose elicits a reduction of intake seems to be localized on the luminal side of the intestinal mucosa, outside of the direct neural afferent activation locale. Therefore, a paracrine or endocrine product of intestinal origin must interfere in vagal afferent signaling. The identity of such a product or products is not certain, however, neuroactive modulators released in response to intestinal stimulation are the most obvious candidates (60) . Duodenal carbohydrate solutions stimulate the release of several putative gastrointestinal (GI) hormones and neuropeptides that contribute to the negative feedback control of food intake (62) , one of which is the brain-gut indoleamine serotonin (5-hydroxytryptamine, 5-HT) (21, 46, 49, 52, 55, 80) .
The serotonergic system has been well studied for its important role in the control of food intake. For example, administration of agonists activating post-synaptic 5-HT receptors produces marked reductions in food intake (4, 64, 68) . Likewise, administration of 5-HT receptor antagonists has been shown to elicit food intake in rats (20, 26) . Systemic serotonergic activity has been shown to induce an anorectic response through activation of a number of receptors, including the excitatory, ligand-gated, cation channel 5-HT 3 receptor (1, 37, 80). 5-HT 3 receptors are predominantly located on terminals of vagal afferent fibers (10, 28, 34, 61) in addition to distinct subpopulations in the brain (9, 56, 58) . This receptor class has been shown to be involved in mediating GI functions such as gastric emptying, pancreatic secretion, and colonic transit (29, 61, 80) , and have also been shown to be involved in the control of intake under a variety of feeding paradigms. For instance, 5-HT 3 receptors mediate anorectic responses to dietary amino acid deficiency (1, 2, 19) , as well as peripheral CCK administration (17, 38, 39) .
There is also some preliminary data demonstrating that 5-HT 3 receptors mediate suppression of intake following intestinal preloads of a nutritionally complete meal (7) . While these findings suggest that endogenous 5-HT, in response to intraintestinal nutrients, participates in the control of food intake via 5-HT 3 receptor activation, it is not clear whether specific nutrient classes or their digestive by-products activate the 5-HT 3 receptor to bring forth short-term reductions in food intake.
Conversely, the products of carbohydrate digestion, in particular, have been shown to mediate feeding related GI functions via 5-HT 3 receptor activation. Functional evidence indicates that 5-HT 3 receptors are involved in initiation of intestinal feedback inhibition of gastric empting (61) and stimulation of pancreatic secretion (46) in response to intestinal perfusion with glucose, and maltose solutions, respectively. Furthermore, electrophysiological studies have shown that activation of vagal afferent fibers by the products of carbohydrate digestion is abolished by the administration of a 5-HT 3 receptor antagonist (80) . Given this evidence, it is conceivable that 5-HT 3 receptors are functionally important in mediating intestinal feedback inhibition of food intake in response to carbohydrates. However, there are no reports that directly demonstrate whether a highly selective 5-HT 3 receptor antagonist can attenuate the reduction of intake resulting from complex carbohydrates (glucose polymers) or monosaccharides (glucose) delivered into the proximal intestine.
Therefore, our present studies were designed to investigate participation of 5-HT 3 receptors in carbohydrate-induced suppression of food intake. Specifically, we examined whether the reduction of intake following an intraintestinal infusion of Polycose (glucose polymers) could be attenuated via blockade of 5-HT 3 receptors. Additionally, we tested the contribution of luminal Polycose hydrolysis and free glucose on 5-HT 3 receptor mediated suppression of intake. Finally, we explored whether glucose absorption was required to suppress food intake through 5-HT 3 receptor activation.
METHODS

Animals and Surgical Preparation
Adult (250-350 g) male Sprague Dawley rats (Harlan, Indianapolis, IN) were housed individually in hanging wire bottom cages and adapted to a 12:12 light-dark cycle (lights on at 06:00) in a temperature-controlled vivarium. Rats had ad libitum access to pelleted rodent chow (Purina, 5001) and water, except as indicated in the experimental procedure when they were deprived of food but not water overnight (17 h). Once acclimated to laboratory conditions, rats were fitted with chronic duodenal catheters, consisting of a 22-cm length of silicone rubber tubing [0.025 in (ID), 0.047 in (OD), Dow Corning, Midland, MI] as described previously by Yox and Ritter (78) . Catheters were inserted 2-cm distal to the pylorus and advanced 6-cm within the duodenal lumen in an aborad direction. The exposed end of the catheter exited through a skin incision over the dorsal aspect of the cranial portion of the neck and was occluded with a stainless steel wire (obturator), which was removed only for flushing of the catheter and infusions. A minimum of seven days was allowed for recovery during which rats attained their pre-operative body weights before the experiments began. This protocol was approved by The Pennsylvania State University Institutional Animal Care and Use Committee. Intestinal Infusions. Polycose (Ross Laboratories, Columbus, OH) was diluted with distilled water to 132, and 263mM concentrations. Acarbose, an alpha-glucosidase inhibitor was isolated via centrifugation of dissolved Precose tablets (100mg, Bayer; Burns Veterinary) and delivered intra-intestinally in 0.2 % (w/v) concentrations, as described previously (53, 63) . In experiments investigating intestinal glucose transport inhibition, phloridzin (Sigma Chemical, St.
Louis, MO) a competitive SGLT 1 inhibitor, was infused at 0.39% (w/v) concentrations, as previously described (63) . Sodium chloride was added to each infusion solution as needed to yield an isosmotic solution (~300 mOsmol). Glucose (Sigma) and mannitol (Sigma) solutions were infused in 308, 694, and 990mM concentrations. Intestinal nutrient concentrations were selected based on their efficacy to suppress 60-minute intake in food-deprived rats, as determined in pilot studies by our laboratory. All infusates were prepared immediately prior to testing and made to a pH of 7.35-7.40.
General Procedure
Overnight food-deprived (17h) rats were given an i.p. injection of either saline or ondansetron five minutes before the initiation of the intraintestinal infusion. Infusates were delivered at a rate of 0.4ml/min for 20 minutes. This infusion rate has been shown to be within the physiological range of gastric emptying (42) . After infusion ceased, rats were returned to their homecages, immediately presented with 15% sucrose in a graduated drinking burette and intake was measured to the nearest 0.1 ml over the subsequent 60 min. Treatments (ondansetron injection and/or nutrient infusion) were separated by saline injection combined with an isotonic (150mM) saline infusion (saline/saline), and each experimental trial was separated by 48 hours.
A minimum of two repetitions of each injection/infusion combination were conducted for each experiment. Thus, each experimental datum represents the mean sucrose intake (± SE) from at least two tests separated by saline/saline control tests. In the studies presented here, the effect of ondansetron on carbohydrate-induced suppression was significant only during the latter half of the sixty minute period ( Figure 6 ). Therefore, with the exception of experiment four, only 60 min data are presented.
Experiments
Four experiments were performed. The first experiment tested the hypothesis that the reduction of feeding in response to intraintestinal Polycose infusion occurs via a 5-HT 3 receptor mediated mechanism. One group of rats (n=6) received an injection of saline or ondansetron (1.0 mg/kg) followed by intraintestinal infusion of either saline, 132mM, or 263mM Polycose administered in ascending order of osmotic concentration. In a separate group of rats (n=10), the effects of ondansetron across a range of doses (0.125, 0.25, 0.5, 1.0, 2.0 and 5.0 mg/kg) on 263mM Polycose-induced suppression of sucrose intake were examined.
The second experiment examined whether the products of luminal glucose polymer hydrolysis were necessary to reduce food intake via 5-HT 3 receptor activation. Rats previously used in infusion experiments (n=12) received an injection of saline or ondansetron (1.0 mg/kg) followed by infusion of solutions that included the alpha-glucosidase inhibitor acarbose (0.2%) either alone or in combination with 263mM Polycose.
To further assess 5-HT 3 receptor participation in the reduction of food intake in response to products of glucose polymer hydrolysis, the next experiment was performed to test the hypothesis that free luminal glucose suppresses intake through 5-HT 3 receptor. Infusates up to this point have been delivered in isosmotic concentrations given that high luminal osmolarity alone has been shown to release 5-HT (52), and elicit 5-HT 3 receptor activation (46, 61) . Since glucose has a molecular weight approximately five times less than that of Polycose, it is not possible to infuse glucose across increasing satiating concentrations while maintaining isotonicity. Therefore, to control for the osmotic properties and establish whether the satiating effect was specific to glucose, the same osmotic concentrations of mannitol were also tested. In the third experiment, experimentally naive rats (n=6), were infused with glucose or mannitol in 0, 308, 694, or 990mM concentrations following an injection of saline or ondansetron.
The final experiment explored whether 5-HT 3 receptors participate in the suppression of intake when active, Na + -dependent absorption of duodenal glucose is inhibited using phloridzin, the competitive SGLT 1 inhibitor. Phloridzin is a useful tool in the study of intestinal glucose transport because it competitively binds SGLT 1 and inhibits its activity (44) . In this experiment, rats (n=12) were injected with either saline or ondansetron (1.0 mg/kg) prior to duodenal infusion of either saline, 990mM glucose, phloridzin (0.39%) or glucose combined with phloridzin.
To determine phloridzin's efficacy in intestinal glucose transport inhibition, blood glucose levels were measured in response to infusions of saline, 990mM glucose, phloridzin (0.39%) or glucose combined with phloridzin. Blood glucose was measured in a drop of tailblood obtained serially from each rat at 0, 20, 30, 45, 60, and 120 minutes relative to the start of the infusion, using a handheld glucometer (LifeScan, Inc. Milpitas, CA).
Analysis of Results
Data for each respective experiment were analyzed separately. Sucrose intake (ml) for each rat was subjected to a two-way repeated-measures analysis of variance (rmANOVA), with drug injection and intestinal infusate as independent variables, using PC-SAS (version 8.02, SAS Institute, Carey, NC) mixed procedure. Blood glucose data (mg/dL) for each rat was subjected to a two-way rmANOVA with infusion condition and time as independent variables. Significant differences among treatment means (adjusted) were analyzed by pairwise t-test for planned comparisons with P< 0.05 considered statistically significant.
RESULTS
In all experiments, when rats received ondansetron prior to intestinal saline infusion, intake was not significantly different from control (saline injection/saline infusion) at any time Table 1 ). Figure 1 , infusion of 132mM Polycose significantly suppressed 60 min intake (7.6 ± 0.6 ml), compared to intake under control conditions (12.6 ± 0.3 ml, P <0.001). Pretreatment with ondansetron (1.0 mg/kg) did not significantly alter this suppression (8.3 ± 0.4 ml, P =0.45).
Effects of 5-HT 3 receptor blockade on Polycose-induced inhibition of food intake
Infusion with 263mM Polycose significantly suppressed intake (2.3 ± 0.5 ml, P<0.001) compared to saline. This suppression was significantly attenuated following pretreatment with ondansetron (4.6 ± 0.8 ml, P=0.004). Table 1 (Table 1) .
Inhibition of luminal glucose polymer hydrolysis accompanied by 5-HT 3 receptor blockade
There was a significant main effect of infusion on intake [F (3, infused with 263mM Polycose significantly suppressed 60 min sucrose intake (2.1 ± 0.6 ml) compared to intake under control conditions (12.8 ± 0.3 ml, P <0.0001). This suppression was significantly attenuated following pretreatment with 1.0 mg/kg ondansetron (4.4 ± 0.9 ml, P =0.019; Figure 3) . A combined infusion of 0.2% acarbose and 263mM Polycose resulted in a significant suppression of sucrose intake (10.4 ± 0.8 ml, P =0.0015) compared to control.
Pretreatment with ondansetron did not significantly alter this suppression (10.0 ± 0.9 ml, P =0.65). Infusion of acarbose alone resulted in sucrose intake which was not significantly different from control when rats were injected with saline (12.2 ± 0.9 ml, P =0.44), or ondansetron (13.3 ± 0.6 ml, P =0.22). Figure 4 , infusion of 308mM glucose resulted in 60 min sucrose intake (12.5 ±0.5 ml) that was less than intake under control conditions (13.4 ±0.2 ml), but this difference was not significant (P =0.052). Pretreatment with 1.0 mg/kg ondansetron did not significantly change this intake (12.3 ±0.5 ml, P =0.84). Similarly, sucrose intake was not suppressed when rats were infused with 308mM mannitol (14.7 ± 0.6 ml, P =0.09). Pretreatment with ondansetron did not alter this intake (13.0 ± 0.8 ml, P =0.15). Infusion of 694mM glucose significantly suppressed intake (10.0 ±0.7 ml, P <0.0001) compared to control, and pretreatment with ondansetron did not significantly alter this suppression (10.4 ± 1.3 ml, P =0.69). Likewise, infusion of 694mM mannitol suppressed intake (11.3 ± 1.1 ml, P =0.001) compared to control.
Effects of 5-HT 3 receptor blockade on glucose-induced inhibition of food intake
This suppression was not changed by pretreatment with ondansetron (12.2 ± 0.7 ml, P =0.43).
The 990mM glucose infusion markedly suppressed sucrose intake (0.4 ± 0.1 ml, P <0.001), which was significantly attenuated by pretreatment with ondansetron (4.4 ± 0.7 ml, P =0.005).
Infusion with 990mM mannitol also significantly suppressed sucrose intake (5.0 ± 0.8 ml, P <0.001), but this suppression was not altered following pretreatment with ondansetron (4.8 ± 1.2 ml, P =0.89). Figure   5 , infusion with the competitive SGLT 1 inhibitor phloridzin produced 60 min intake (17.3 ± 1.4 ml) similar to that of control (18.0 ± 0.7 ml, P =0.3). This intake was not altered by pretreatment with 1.0 mg/kg ondansetron (15.7 ± 1.3 ml, P =0.16). Infusion of 990mM glucose significantly suppressed sucrose intake (4.3 ± 1.0 ml, P <0.001) compared to intake following control treatment. The suppression of intake following 990mM glucose infusion was significantly attenuated when rats were pretreated with ondansetron (7.7 ± 1.0 ml, P =0.002). When rats were infused with phloridzin in combination with 990mM glucose, sucrose intake was significantly suppressed (4.9 ± 1.0 ml, P <0.001) compared to control but not different from glucose infusion alone (P =0.58). The suppression of intake resulting from glucose plus phloridzin infusion was significantly attenuated when rats were pretreated with ondansetron (7.5 ± 1.3 ml, P =0.018). showed that ondansetron attenuated suppression of food intake in response to intraintestinal infusion of free luminal glucose and this response was not altered by blocking active glucose absorption.
Effects of 5-HT 3 receptor blockade on glucose-induced reduction of food intake while inhibiting active intestinal glucose transport
In a broader context, the findings of this study corroborate with those from other laboratories (1, 7, 8, 17 ) as well as our own (38, 39) , demonstrating that 5-HT 3 (35, 41) . In one of these studies in which food consumption was a secondary outcome measured, 0.01 -1.0 mg/kg doses of ondansetron treatment alone produced no effect on food intake (35) . Furthermore, studies examining the effects of much lower doses of ondansetron on food intake are equally inconsistent. For instance, in one study, administration of ondansetron (30 and 100 µg/kg) significantly increased sweetened mash intake and decreased 3% sucrose solution intake (10 and 30 µg/kg) in non-food-deprived rats (14) The exact anatomical site of ondansetron's effects on carbohydrate-induced suppression of intake cannot be determined from the present studies. While pharmacokinetic studies indicate that ondansetron exhibits limited penetration of the blood brain barrier (65) , some reports suggest that central 5-HT 3 receptors are blocked by peripherally administered 5-HT 3 receptor antagonists (15, 75) . Conversely, there is no change in food intake when a highly selective 5-HT 3 receptor agonist, m-chlorophenylbiguanide hydrochloride (1-(3-chlorophenyl)biguanide (m-CPBG), is administered into the third ventricle (9). However, this evidence does not permit us to entirely discount any central 5-HT 3 receptor participation in the current study. Electrophysiological, immunocytochemical, and autoradiographic studies have revealed that 5-HT 3 receptors are extensively located throughout the rat brain (24, 45) including areas related to control of food intake, such as the hindbrain and the hypothalamus (58, 69) . Furthermore, the NTS expresses binding sites for 5-HT 3 ligands (6, 45) and is densely innervated by serotonergic terminals (67, 69) . Given that minute amounts of ondansetron may permeate the blood brain barrier (25) , further investigation is surely warranted to directly examine participation of hindbrain 5-HT 3 receptors in the control of food intake, including suppression of intake resulting from intestinal carbohydrates.
Blockade of 5-HT 3 receptors in the absence of intestinal carbohydrate infusion had no significant effect on sucrose consumption at any dose of ondansetron tested. This is in agreement with our laboratory's previous work (38, 39) as well as that of others (7, 17) showing that administration of ondansetron in equivalent doses did not alter intake compared to control. Since ondansetron (1.0 mg/kg) does not increase sucrose intake in non-food-deprived rats (39), it is not likely that an orexigenic effect of ondansetron was masked due to a ceiling effect resulting from overnight food-deprivation. Furthermore, simultaneous administration of CCK-1 and 5-HT 3 receptor antagonists produces intake greater than that of control in food-deprived rats (39) showing that sucrose intake following overnight deprivation is not at its upper limit per se. Thus, it is not likely that our observations result from independent, additive orexigenic and anorexigenic effects of ondansetron and nutrient infusion respectively, given that ondansetron attenuated the suppression of intake only when rats were infused with higher concentrations of carbohydrate solutions. Instead, our results imply that the feeding effects evoked by 5-HT 3 receptor antagonism are due to inhibition of anorectic signals arising from intestinal carbohydrate-induced activation of 5-HT 3 receptors.
Consistent with the findings of others (53, 62, 63) , we found that administration of the competitive alpha-glucosidase inhibitor, acarbose, attenuated reduction of food intake by intestinal Polycose. This feeding effect of a combined infusion of acarbose and Polycose was maintained when rats were pretreated with ondansetron. We reason that hydrolysis of glucose polymers to the monosaccharide, glucose is necessary to elicit reduction of food intake mediated through 5-HT 3 receptors. Supporting this notion is the fact that suppression of intake following duodenal infusion of free luminal glucose was attenuated by blockade of 5-HT 3 receptors.
While the mechanism by which 5-HT is released in response to intestinal glucose remains unclear, there is some evidence that luminal SGLT 1 may be a factor. Specifically, Kim and colleagues (43) , employing an enterochromaffin cell model demonstrated that glucose stimulates a concentration dependent release of 5-HT, and that this response was inhibited by treatment with phloridzin. In our final experiment, we sought to examine whether active glucose absorption by SGLT 1 was necessary to elicit 5-HT 3 receptors to reduce food intake. Here, duodenal infusion of phloridzin attenuated glucose-induced suppression of intake. This effect was immediate while transport of glucose into the blood was markedly inhibited to the level of blood glucose following saline infusion. It is conceivable that blocking active glucose absorption with phloridzin attenuated the immediate glucose-induced suppression of intake by impeding receptors triggers a positive feedback mechanism leading to an increase of 5-HT release (23, 54) , the attenuation of glucose-induced suppression by ondansetron in our study may have resulted from inhibition of 5-HT release. This notion, along with the inhibitory effect phloridzin has on 5-HT release (43) , could elucidate why ondansetron plus phloridzin had the greatest effect on glucose-induced suppression of intake. In other words, some but not all glucose-induced 5-HT release was independently inhibited by ondansetron or by phloridzin treatments alone, and this effect was potentiated when these treatments occurred concurrently. While blockade of 5-HT 3 receptors did independently produce a significant inhibition of glucose-induced suppression of intake in the presence or absence of phloridzin, we can only speculate the role of 5-HT release and its activity in our study. However, on the basis of the evidence presented here we can conclude that intestinally infused glucose suppresses intake partly through a pre-absorptive activation of 5-HT 3 receptors.
Since 5-HT 3 receptors have been shown to be responsive to hyperosmolar liquids to mediate GI functions (46, 49, 61) , whenever possible, we chose to infuse solutions that were isosmotic to luminal osmolarity. Although we did not directly measure osmoconcentration of our solutions in the duodenum, it has been shown that infusion of glucose polymer solutions result in lower luminal osmolarity than infusion of glucose solutions of the same concentration by weight (18) and that duodenal infusion of hypertonic glucose solutions produce a maximal duodenal osmoconcentration much lower than that of the solution infused (18, 40) . In our study, ondansetron attenuated the suppression induced by 263mM Polycose as well as 990mM glucose, but not 990mM mannitol. This suggests that the feeding responses observed when we infused a solution with a high osmotic concentration, or potentially high luminal concentration, were not due to osmotic activation of the 5-HT 3 receptors. Additionally, experiment 3 revealed that 1.0 mg/kg ondansetron attenuated glucose-induced suppression of intake to the level of mannitolinduced suppression of intake, suggesting that glucose itself and not simply the colligative properties of the infusate are eliciting activation of 5-HT 3 receptors to inhibit food intake.
In conclusion, the present studies demonstrate that 5-HT 3 receptors participate in food intake inhibition in response to intraintestinal infusion of both glucose polymer and glucose solutions. We determined that suppression of feeding due to infusion of Polycose as mediated Polycose-induced suppression of intake (see Table 1 ). Suppression of intake was not significantly attenuated by the lower doses of ondansetron tested although difference scores for all doses were statistically similar (one way rmANOVA, P=0.91). 
